In-vitro susceptibility of E. coli, Shigellae and Salmonellae to kanamycin and therapeutic implications.
D000667:Ampicillin / Q000494:pharmacology; D002701:Chloramphenicol / Q000494:pharmacology; D003091:Colistin / Q000494:pharmacology; D004405:Dysentery, Bacillary / Q000188:drug therapy; D004926:Escherichia coli / Q000187:drug effects*; D004927:Escherichia coli Infections / Q000188:drug therapy; D006801:Humans; D007223:Infant; D007612:Kanamycin / Q000494:pharmacology*; D009355:Neomycin / Q000494:pharmacology; D010406:Penicillins / Q000494:pharmacology; D012475:Salmonella / Q000187:drug effects*; D012760:Shigella / Q000187:drug effects*; D013411:Sulfadiazine / Q000494:pharmacology; D013752:Tetracycline / Q000494:pharmacology
D010406:Penicillins; D013411:Sulfadiazine; D007612:Kanamycin; D002701:Chloramphenicol; D000667:Ampicillin; D013752:Tetracycline; D009355:Neomycin; D003091:Colistin